Pembrolizumab Biosimilar(Rophibio)

帕博利珠单抗生物类似药（Rophibio）

Report date: 2025/02/18 10:49:58

Base Information

Drug NamePembrolizumab Biosimilar(Rophibio)

Drug Alias NameRBS-003

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRophibio Inc

China Registration ClassN/A

Active CompaniesRophibio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeL01FF02L01XC18